Matching articles for "Reactine"
Issue 1725 · March 31, 2025 Free
Treatment of Allergic Rhinitis and Allergic Conjunctivitis

Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):49-56 doi:10.58347/tml.2025.1725a
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1622 · April 19, 2021
Drugs for Allergic Rhinitis and Allergic Conjunctivitis

The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).

Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Issue 1595 · April 6, 2020
Intravenous Cetirizine (Quzyttir) for Acute Urticaria

Quzyttir (TerSera), an IV formulation of the second-generation H 1 -antihistamine cetirizine, has been approved by the FDA for treatment of acute urticaria in patients ≥6 months old. Oral formulations of…

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):55-6
Quzyttir (TerSera), an IV formulation of the second-generation H 1 -antihistamine cetirizine, has been approved by the FDA for treatment of acute urticaria in patients ≥6 months old. Oral formulations of cetirizine ( Zyrtec , and others) have been for sale over the counter for years. Quzyttir is the first parenteral formulation of a second-generation H 1 -antihistamine to become available in the US; parenteral formulations of two first-generation H 1 -antihistamines, diphenhydramine ( Benadryl , and others) and hydroxyzine ( Vistaril , and others), have been available for many years.
Issue 1570 · April 22, 2019
OTC Drugs for Seasonal Allergies

Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter…

Med Lett Drugs Ther. 2019 Apr 22; 61(1570):57-60
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter (OTC) for relief of symptoms. Prescription products for management of allergic rhinitis and allergic conjunctivitis are reviewed separately.
Issue 1365 · May 30, 2011 Free
In Brief: Fexofenadine (Allegra) and Fruit Juice

Fexofenadine ( Allegra , and others) is the most recent second-generation H 1 -antihistamine to become available over the counter (OTC). Cetirizine ( Zyrtec , and others) and loratadine ( Claritin , and…

Med Lett Drugs Ther. 2011 May 30; 53(1365):41
Fexofenadine ( Allegra , and others) is the most recent second-generation H 1 -antihistamine to become available over the counter (OTC). Cetirizine ( Zyrtec , and others) and loratadine ( Claritin , and others) are already available OTC. Cetirizine can be sedating in usual doses. Loratadine can be sedating in higher-than-usual doses. Fexofenadine remains nonsedating even in higher doses.
Issue 1331 · February 8, 2010
Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine

Bepotastine besilate 1.5% ophthalmic solution ( Bepreve - ISTA Pharmaceuticals), an H 1 -antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in…

Med Lett Drugs Ther. 2010 Feb 8; 52(1331):11-2
Bepotastine besilate 1.5% ophthalmic solution ( Bepreve - ISTA Pharmaceuticals), an H 1 -antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.
Issue 1310 · April 20, 2009
Azelastine (Astepro) Nasal Spray for Allergic Rhinitis

A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray ( Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old…

Med Lett Drugs Ther. 2009 Apr 20; 51(1310):29-30
A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray ( Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old and is being heavily advertised to the public on radio, television and the Internet. All azelastine products require a prescription.
Issue 1289 · June 30, 2008
Olopatadine (Patanase) Nasal Spray

Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity,…

Med Lett Drugs Ther. 2008 Jun 30; 50(1289):51-2
Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity, olopatadine is already marketed for treatment of allergic conjunctivitis in a 0.1% solution as Patanol and in a 0.2% solution as Pataday. Azelastine (Astelin) , another H1-antihistamine with mast-cell stabilizing activity, has been available for intranasal treatment of allergic rhinitis since 1997.